Our haematology service covers a population of one million and offers specialist services to one and a half million patients.
Our core functions are stem cell transplantation, haemophilia care, haemoglobinopathy and paediatric, teenage and young adult cancer.
The Osborne unit at Leicester Royal Infirmary holds 21 inpatient beds, and a day case unit providing outpatient and ambulatory care. We also provide diagnostic and therapeutic care, blood transfusions and apheresis, with a dedicated haemophilia and thrombosis unit.
We continually strive to improve our service provision and work in collaboration with our primary care partners. Some of the most recent improvements include EMPATH guidelines and a link to online advice with every abnormal blood count. We have also established a one-stop diagnostic service called HMDL for Leicestershire and are helping Nottingham to establish a similar integrated diagnostic service.
We are in the process of launching the DAWN monitoring system for remote monitoring of paraprotein and lymphocyte count and have a strong virtual clinic alongside our main clinic.
The team consists of 15 consultants and two associate specialists, each specialised within haematology and recognised nationally and internationally in their respective fields.
We also have an extended team of specialist nurses, with connections to the haematological malignancy diagnostic links service.
A wide range of conditions are studied in Leicester’s hospitals including malignant, non malignant and laboratory haematology.
We offer regular educational meetings and a weekly seminar series, as well as providing undergraduate teaching in conjunction with the University of Leicester. Our commitment to audit means we have good pass rates.
We have a very healthy research portfolio in malignant as well as non-malignant haematology and have played a major role in getting CR-UK and Myeloma UK centre status. We conduct active clinical trials research, encompassing early phase trials of novel agents, with a large portfolio of phase three trials. Our SpRs also have the opportunity to conduct a period of research as research clinical fellows.
Our Ernest and Helen Scott Haematological Research Institute focuses on lymphoid malignancies and the new and exciting therapeutics arising out of our research.
We run phase one and two trials in our HOPE trials unit and take part in the majority of NCRN trials. This brings treatment to patients years before it is available on the NHS, or through NICE or CDF. By taking part in these trials we save up two million pounds worth of drug expenditure for the CCG.